<DOC>
	<DOCNO>NCT00450827</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , iodine I 131 monoclonal antibody 3F8 bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth neuroblastoma block blood flow tumor . Giving iodine I 131 monoclonal antibody 3F8 together bevacizumab may kill tumor cell . PURPOSE : This phase I trial study side effect best dose iodine I 131 monoclonal antibody 3F8 give together bevacizumab treat patient relapsed refractory neuroblastoma .</brief_summary>
	<brief_title>Iodine I 131 Monoclonal Antibody 3F8 Bevacizumab Treating Patients With Relapsed Refractory Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity iodine I 131 monoclonal antibody 3F8 ( ^131I-3F8 ) bevacizumab patient relapse refractory neuroblastoma . - Determine hematopoietic recovery autologous stem cell rescue patient treated regimen . Secondary - Determine clinical response rate patient treated regimen . - Assess whole body dosimetry ^131I-3F8 . - Assess tumor target ^131I-3F8 bevacizumab . OUTLINE : This dose-escalation study iodine I 131 monoclonal antibody 3F8 ( ^131I-3F8 ) . Patients receive ^131I-3F8 IV 20-30 minute day 0 bevacizumab IV 30-90 minute day 1 15 . Treatment repeat every 28 day 4 course . Patients whose blood count recover whose human antimouse antibody ( HAMA ) titer &lt; 1,000 U/mL course 1 receive one dose ^131I-3F8 alone follow autologous stem cell rescue ( ASCR ) filgrastim ( G-CSF ) . Patients whose blood count recover whose HAMA titer ≥ 1,000 U/mL course 1 undergo ASCR follow G-CSF . Patients whose blood count recover whose HAMA titer &lt; 1,000 U/mL course 1 receive 3 course ^131I-3F8 bevacizumab absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos ^131I-3F8 bevacizumab maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow 3-4 week every 3-6 month thereafter .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject Patients must diagnosis NB accordance International Criteria , i.e. , either histopathology ( confirm MSKCC Department Pathology ) BM involvement plus elevated urinary catecholamine . Must history tumor progression recurrence failure achieve complete response standard therapy . Patients must evaluable ( microscopic marrow metastasis , MIBG PET scan ) measurable ( CT , MRI ) disease . Prior Therapy : At least 2 week elapse since biologic therapy . Three week elapse since last dose chemotherapy radioimmunotherapy . Age &gt; 1 year able cooperate radiation safety restriction therapy period . Stem cell : Patients must autologous hematopoietic stem cell product cryopreserved available reinfusion MIBG treatment . The minimum dose hematopoietic stem cell 2 X106 CD34+ cells/kg . Minimum life expectancy four week . Signed informed consent indicate awareness investigational nature program . Subject Severe major organ toxicity . Renal , cardiac , hepatic , pulmonary , gastrointestinal neurologic toxicity grade 2 less ( per NCI CTC version 3 criterion ) . Specifically , serum creatinine ≤3 x upper limit normal ( ULN ) , serum AST ALT ≤5 x ULN , serum bilirubin ≤ 3 x ULN , LV shorten fraction ≥15 % . Patients myelosuppression exclude ANC ≥ 500/uL . Platelet count &gt; 50,000/ul hemoglobin &gt; 8gm/dl . Patients may receive platelet red blood cell transfusion maintain hemoglobin platelet clinical appropriate level . Patients document chronic nonhealing wound , ulcer bone fracture Surgical procedure . Patients undergone major surgery &lt; 28 day prior begin therapy bevacizumab exclude . Patients must least 24 hour surgical procedure placement central catheter . Patients &lt; 7days minor surgery ( e.g . fine needle core biopsy ) and/or unhealed wound procedure exclude . Patients exclude major surgery ( e.g . abdominal thoracic surgery resection tumor ) anticipate course study . Known bleed diathesis coagulopathy . Patients anticoagulant ( except heparin flush centra venous catheter maintenance ) exclude . Thrombosis : patient must deep venous arterial thrombosis ( noncentral venous catheter relate ) within last three month prior study entry . Patients cerebrovascular accident transient ischemic attack within 6 month therapy exclude . Patients history peripheral vascular disease , myocardial infarction unstable angina exclude . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study entry . Pulmonary CNS metastasis : pretherapy CT MRI head chest must carry . Proteinuria : Urine protein : creatinine ratio ≥ 1.0 Uncontrolled hypertension . HAMA &gt; 1000 ELISA units/ml . History allergy mouse protein , Chinese hamster ovary cell product recombinant human antibody Active serious infection control antibiotic . Pregnant woman exclude fear danger fetus . Therefore negative pregnancy test require woman childbearing age , appropriate contraception use study period . Inability unwillingness comply radiation safety procedure protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>